Other biomarkers sometimes associated with clinical response to anti-PD-1, such as TMB or total CD8+ T cell infiltration in the tumor microenvironment, were analyzed in this cohort of patients treated with anti-PD-1 alone. The gene discussed is CD8A; the disease is neoplasm.